Clinikally is a dermatology telehealth and e-pharmacy startup based in Gurugram, India, that connects consumers with dermatologists and sells prescription-grade skin, hair and wellness products.

This Startup Deep Dive explains what Clinikally does, how it makes money, who backs it, how it compares with rivals and what could go wrong, using publicly available information. It is educational and not investment advice. Last updated: October 2026.

Clinikally in Brief

• What it is: Clinikally is an Indian Dermatology telehealth e-pharmacy company based in Gurugram.
• Who it serves: patients, doctors, hospitals, diagnostic centres, insurers and employers.
• Clinikally connects individuals with dermatologists for personalised treatment of conditions such as acne, hair loss, hyperpigmentation, eczema, rosacea and melasma.
• It sells prescription-grade skincare, haircare and wellness products, including immunity and nutrition items.
• It partners with pharmacies and consumer brands and uses AI-powered recommendations for select over-the-counter products to build automated treatment plans.
• Funding: Reported USD 3.1 million across 3 rounds (per one startup database).

Clinikally Quick Facts

Figures marked “reported” come from published reports and may differ between sources; “Not disclosed” means no reliable public figure was found.

What Is Clinikally?

Clinikally operates in the Dermatology telehealth e-pharmacy space in India. Understanding a company like this starts with three questions: who is the customer, what painful problem is being solved, and why the solution is better than the alternatives. The sections below apply that lens to Clinikally.

• Clinikally connects individuals with dermatologists for personalised treatment of conditions such as acne, hair loss, hyperpigmentation, eczema, rosacea and melasma.
• It sells prescription-grade skincare, haircare and wellness products, including immunity and nutrition items.
• It partners with pharmacies and consumer brands and uses AI-powered recommendations for select over-the-counter products to build automated treatment plans.

The Origin Story of Clinikally

Every company starts from a noticed gap and a team willing to commit to closing it. Strong origin stories are specific: a clear problem, a founding team with relevant skills, and an early product that real customers could test. Founder-market fit, meaning the team’s lived experience or technical depth in the domain, tends to predict how fast a young company learns.

• Founders: Arjun Soin.
• Arjun Soin launched Clinikally in 2021.
• One report says it was part of Y Combinator's summer 2022 batch.

Key Milestones and Challenges

No startup grows in a straight line. Early years usually involve slow adoption, product rewrites, hiring mistakes and funding gaps. In the Dermatology telehealth e-pharmacy sector the common turning points are a first paying customer, a regulatory approval, a successful product demonstration or a funding round that lets the team invest ahead of demand. How a team responds to setbacks says more about resilience than any single headline.

• September 2023: raised USD 2.6 million in a round led by Y Combinator and Tribe Capital with other investors (reported).
• By September 2023 the company claimed more than 450,000 users across 500 cities within 21 months of launch (company-stated).

Clinikally Funding and Investors

Funding history shows how much outside confidence a company has attracted and how long it can operate before needing more capital. Figures below are reported and may differ between sources; valuation figures are estimates unless the company has confirmed them.

• Reported: an earlier USD 500,000 round from investors including Parento Holdings, Sumant Sinha, Anu Acharya and Gautam Trivedi.
• Reported: USD 2.6 million in September 2023 from Y Combinator, Tribe Capital, Goodwater Capital, Sequoia Scout Fund and Rebel Fund, with angels including Arash Ferdowsi, Kunal Shah, Austen Allred and Qasar Younis.

How Does Clinikally Make Money? (Business Model)

A business model describes who pays, how often and how much it costs to serve them. Strong models show repeat usage, improving margins with scale and acquisition channels that do not depend only on paid spend. Weak models show one-off sales, rising costs and growth that stops when spending stops. For companies selling to patients, doctors, hospitals, diagnostic centres, insurers and employers, sales cycles and contract size matter as much as headline growth.

• Telehealth consultations combined with an e-pharmacy and sale of dermatology products.
• Partnerships with pharmacies and consumer brands.

The Numbers: Clinikally Financials

Financial figures show whether growth is turning into a self-sustaining business. Small and private companies often disclose little, so any number below is included only if it was found in public reporting.

• Revenue of Rs 31.1 crore in FY25, up 84.4% from Rs 16.8 crore in FY24 (reported).
• More than 450,000 users across 500 cities as of September 2023 (company-stated).

Market Opportunity for Clinikally

Market size is easy to exaggerate, so a useful approach separates the total market from the portion a company can realistically reach with its current product and distribution. The main forces behind demand in this sector are rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings. Each of these widens the opportunity, but capital efficiency and execution decide who captures it.

• A cited Statista projection puts Indian healthtech revenue at USD 31 billion by 2028.

Technology and Product at Clinikally

Technology is rarely the whole moat, but it drives speed, cost and customer experience. A practical way to assess it is to separate the capability the company controls from the commodity infrastructure it rents. In this sector the important factors are clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

• AI-powered automated treatment plans built on a proprietary database of prescriptions (company-stated).
• Telehealth platform with omnichannel capabilities and offline clinic collaborations (company-stated plans).

Team and Culture at Clinikally

Teams are the most important and least measurable asset of a young company. Look at how complementary the founders’ skills are, how deep the second layer of leadership is, and how the company hires and retains specialists. Culture shows up in small repeated behaviours: how quickly bad news travels upward and whether commitments to customers are kept.

• Arjun Soin is the founder.

Clinikally Competitors: Competitive Landscape

A fair competitive analysis names direct rivals, adjacent players who could move into the space, and the customer’s default alternative. Durable advantages include proprietary data or technology, licences and approvals, brand trust, switching costs and cost leadership.

Risks and Challenges for Clinikally

• Clinikally operates in a competitive online dermatology and skincare market with funded rivals.
• Its reported funding total is modest compared with some peers.
• Regulatory risk: medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules.
• Clinical and liability risk: errors in care, diagnosis or product quality can damage trust quickly.
• Data privacy risk: health records are sensitive, and breaches or misuse can bring legal and reputational harm.

Risk is not a reason to avoid a company; it is a reason to price it correctly and to monitor the right indicators over time. Regulation in this sector is shaped by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Clinikally Growth Outlook: What to Watch

• The company said the 2023 funds would go toward a more robust platform, stronger telehealth technology, omnichannel expansion with offline clinic collaborations, and AI-powered automated treatment plans (company-stated).
• Key indicators: patient or user volumes, repeat usage, gross margin, clinical outcomes and cost of acquiring each customer.
• Funding position: Whether Clinikally can reach its next milestone before needing new capital.
• Regulation: Changes from the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Industry Context: Where Clinikally Fits

India's healthcare market combines a large public system, a fast-growing private hospital sector and an increasingly digital layer. Government initiatives such as Ayushman Bharat and the Ayushman Bharat Digital Mission aim to widen insurance cover and create common digital health records, while telemedicine guidelines and the Digital Personal Data Protection Act shape how digital care and patient data can be used.

Demand is driven by chronic and lifestyle disease, an ageing population, rising insurance penetration and consumers who now expect to book, pay and consult online. Startups in this field compete on trust, clinical quality and convenience, and they must prove outcomes and safety as well as growth.

For readers new to this field, a useful habit is to separate announcements from evidence. A plan, a partnership or a funding headline describes intent, while a delivered product, a paying customer or an audited financial statement describes results. Comparing the two over time shows how reliably a company turns promises into outcomes.

Bull Case and Bear Case for Clinikally

An investment thesis is a short, testable statement of why a company could become far more valuable, together with what evidence would prove it wrong. The points below are general to this sector and are not forecasts for Clinikally.

Bull case

• Rising insurance cover and digital adoption expand the customer base.
• Strong clinical evidence builds trust with doctors and hospitals.
• Scale can improve unit economics in diagnostics and care delivery.

Bear case

• Regulatory changes can alter permitted products or business models.
• Customer acquisition costs can erode margins.
• A single safety or privacy incident can damage trust.

Lessons Founders and Investors Can Take from Clinikally

Studying a company in the Dermatology telehealth e-pharmacy space offers lessons that go beyond any single firm. The points below are general lessons for the sector and are not claims about Clinikally.

• Trust is the real currency in healthcare, so quality control, clinical evidence and data protection must be built in from the start.
• Distribution through hospitals, clinics, insurers or employers can matter more than a standalone consumer app.
• Unit economics improve when repeat usage replaces expensive one-time customer acquisition.
• Regulatory approvals can take time, so timelines and cash planning should allow for them.
• Integration with existing hospital, lab and records systems reduces friction for adoption.

How to Evaluate Clinikally as a Startup

• Customer clarity: Can Clinikally name its customer and the problem it solves in one sentence?
• Evidence of demand: Look for repeat customers, signed contracts or measurable usage rather than announcements alone.
• Economics: Check whether margins improve as volume grows.
• Execution: Compare announced timelines with what has actually been delivered.
• Funding runway: Estimate how long current capital lasts at the present spending rate.
• Regulatory standing: Confirm required approvals are in place.
• Customer concentration: Check whether a few customers account for most of the revenue.
• Management depth: Look for experienced leaders beyond the founders and a stable core team.

The Takeaway

Clinikally is part of India’s growing Dermatology telehealth e-pharmacy ecosystem. The useful lesson from studying it is the discipline of asking structured questions about customers, economics, advantage and resilience. Companies that answer them well, repeatedly and under pressure are the ones that endure. Readers should treat any single report, ranking or funding headline as one input among many, and should re-check key facts against recent company announcements. Because public information on young companies is often limited, patience in verifying claims is part of good analysis. This article is educational and is not investment advice.

• Clear customers and repeat demand matter more than announcements.
• Regulation and capital needs shape how fast a startup in this sector can grow.
• Track a few leading indicators over time rather than one headline metric.

Clinikally FAQs: Frequently Asked Questions

What is Clinikally?

Clinikally is a dermatology telehealth and e-pharmacy startup based in Gurugram, India, that connects consumers with dermatologists and sells prescription-grade skin, hair and wellness products. It is profiled in the Startup Deep Dive series, which explains business model, funding, competitors and risks.

Who founded Clinikally?

Clinikally was founded by Arjun Soin, and the company reports a founding year of 2021.

How much funding has Clinikally raised?

Reported USD 3.1 million across 3 rounds (per one startup database). Funding figures are reported and may differ between sources, so readers should check the latest company announcements.

How does Clinikally make money?

Clinikally earns revenue from its Dermatology telehealth e-pharmacy products and services sold to patients, doctors, hospitals, diagnostic centres, insurers and employers. The exact revenue mix is described in the business model section and is not fully disclosed publicly.

Who are the competitors of Clinikally?

Reported rivals include Cureskin. See the competitor comparison above for how they differ.

What are the main risks for Clinikally?

Main risks include medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules, funding and capital needs, competition and regulation by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act. This is educational content, not investment advice.

Related Startup Deep Dives: Oziva — OZiva: HUL-backed nutrition brand hit Rs 258 Cr in FY25 | Ayurdhara — short profile of what is publicly known. Browse the full Startup Deep Dive series.

Source

Source: Publicly available data, published reports, industry research, and other credible sources.